View Future GrowthBio-Gene Technology 과거 순이익 실적과거 기준 점검 0/6Bio-Gene Technology은 연평균 0.3%의 비율로 수입이 증가해 온 반면, Chemicals 산업은 연평균 0.6%의 비율로 증가했습니다. 매출은 연평균 38.9%의 비율로 감소했습니다.핵심 정보0.26%순이익 성장률11.01%주당순이익(EPS) 성장률Chemicals 산업 성장률14.45%매출 성장률-38.90%자기자본이익률-216.01%순이익률n/a최근 순이익 업데이트31 Dec 2025최근 과거 실적 업데이트Reported Earnings • Aug 01Full year 2023 earnings released: AU$0.018 loss per share (vs AU$0.019 loss in FY 2022)Full year 2023 results: AU$0.018 loss per share. Net loss: AU$3.10m (loss widened 6.2% from FY 2022).Reported Earnings • Feb 24First half 2023 earnings released: AU$0.012 loss per share (vs AU$0.01 loss in 1H 2022)First half 2023 results: AU$0.012 loss per share (further deteriorated from AU$0.01 loss in 1H 2022). Net loss: AU$1.97m (loss widened 37% from 1H 2022). Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has fallen by 17% per year, which means it is performing significantly worse than earnings.Reported Earnings • Aug 18Full year 2022 earnings released: AU$0.019 loss per share (vs AU$0.017 loss in FY 2021)Full year 2022 results: AU$0.019 loss per share (down from AU$0.017 loss in FY 2021). Net loss: AU$2.91m (loss widened 22% from FY 2021). Over the last 3 years on average, earnings per share has fallen by 5% per year whereas the company’s share price has fallen by 1% per year.Reported Earnings • Feb 21First half 2022 earnings: EPS exceeds analyst expectations while revenues lag behindFirst half 2022 results: AU$0.01 loss per share (vs AU$0.01 loss in 1H 2021). Net loss: AU$1.44m (loss widened 8.1% from 1H 2021). Revenue missed analyst estimates by 95%. Earnings per share (EPS) exceeded analyst estimates by 75%. Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has increased by 28% per year, which means it is tracking significantly ahead of earnings growth.Reported Earnings • Aug 27Full year 2021 earnings released: AU$0.017 loss per share (vs AU$0.016 loss in FY 2020)Full year 2021 results: Net loss: AU$2.40m (loss widened 24% from FY 2020). Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth.Reported Earnings • Feb 20First half 2021 earnings released: AU$0.01 loss per share (vs AU$0.009 loss in 1H 2020)First half 2021 results: Net loss: AU$1.33m (loss widened 25% from 1H 2020). Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.모든 업데이트 보기Recent updatesNew Risk • Jan 22New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 14% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$2.5m free cash flow). Earnings have declined by 2.8% per year over the past 5 years. Shareholders have been substantially diluted in the past year (51% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (AU$10.4m market cap, or US$7.06m). Minor Risk Share price has been volatile over the past 3 months (14% average weekly change).Board Change • Jan 05No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. MD, CEO & Director Tim Grogan was the last director to join the board, commencing their role in 2023. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.New Risk • Dec 17New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Australian stocks, typically moving 18% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$2.5m free cash flow). Share price has been highly volatile over the past 3 months (18% average weekly change). Earnings have declined by 2.8% per year over the past 5 years. Shareholders have been substantially diluted in the past year (51% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (AU$7.02m market cap, or US$4.66m).공시 • Sep 30Bio-Gene Technology Limited, Annual General Meeting, Nov 19, 2025Bio-Gene Technology Limited, Annual General Meeting, Nov 19, 2025.New Risk • Sep 19New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 15% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$2.5m free cash flow). Earnings have declined by 2.8% per year over the past 5 years. Shareholders have been substantially diluted in the past year (51% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (AU$9.15m market cap, or US$6.05m). Minor Risk Share price has been volatile over the past 3 months (15% average weekly change).New Risk • Aug 27New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -AU$2.5m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$2.5m free cash flow). Earnings have declined by 2.8% per year over the past 5 years. Shareholders have been substantially diluted in the past year (51% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (AU$6.71m market cap, or US$4.35m).New Risk • Jul 04New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 32% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 6.1% per year over the past 5 years. Shareholders have been substantially diluted in the past year (32% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (AU$4.80m market cap, or US$3.15m). Minor Risk Share price has been volatile over the past 3 months (14% average weekly change).공시 • May 05+ 1 more updateBio-Gene Technology Limited has filed a Follow-on Equity Offering in the amount of AUD 0.69 million.Bio-Gene Technology Limited has filed a Follow-on Equity Offering in the amount of AUD 0.69 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 30,000,000 Price\Range: AUD 0.023 Security Features: Attached OptionsNew Risk • Jan 29New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Australian stocks, typically moving 29% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$2.8m free cash flow). Share price has been highly volatile over the past 3 months (29% average weekly change). Earnings have declined by 9.0% per year over the past 5 years. Revenue is less than US$1m (AU$18k revenue, or US$11k). Market cap is less than US$10m (AU$10.7m market cap, or US$6.65m).New Risk • Dec 17New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$2.8m free cash flow). Earnings have declined by 9.0% per year over the past 5 years. Revenue is less than US$1m (AU$18k revenue, or US$12k). Market cap is less than US$10m (AU$7.65m market cap, or US$4.87m). Minor Risk Share price has been volatile over the past 3 months (12% average weekly change).공시 • Oct 04Bio-Gene Technology Limited, Annual General Meeting, Nov 29, 2024Bio-Gene Technology Limited, Annual General Meeting, Nov 29, 2024.New Risk • May 06New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Australian stocks, typically moving 18% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (18% average weekly change). Earnings have declined by 9.6% per year over the past 5 years. Revenue is less than US$1m (AU$168k revenue, or US$111k). Market cap is less than US$10m (AU$13.9m market cap, or US$9.19m). Minor Risk Shareholders have been diluted in the past year (13% increase in shares outstanding).New Risk • Feb 16New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 7.4% per year over the past 5 years. Revenue is less than US$1m (AU$149k revenue, or US$97k). Market cap is less than US$10m (AU$11.1m market cap, or US$7.22m). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Shareholders have been diluted in the past year (13% increase in shares outstanding).New Risk • Dec 12New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 7.4% per year over the past 5 years. Revenue is less than US$1m (AU$149k revenue, or US$98k). Market cap is less than US$10m (AU$12.1m market cap, or US$7.96m). Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Shareholders have been diluted in the past year (13% increase in shares outstanding).공시 • Nov 23Bio-Gene Technology Limited Approves the Election of Alex Ding as DirectorBio-Gene Technology Limited at its AGM held on November 23, 2023, approved the election of Mr. Alex Ding as a Director.공시 • Nov 15+ 1 more updateBio-Gene Technology Limited Announces Resignation of Rodrigo Valencia as Joint CFOBio-Gene Technology Limited announced the resignation of Mr. Rodrigo Valencia as joint CFO and Company Secretary effective immediately. Mr. Roger McPherson will remain with Bio-Gene, on an interim basis, as the sole CFO and Company Secretary, while the Company seeks a suitable permanent replacement.공시 • Oct 30Bio-Gene Technology Limited Announces the Appointment of Roger Mcpherson as Joint Company SecretaryBio-Gene Technology Limited announced the appointment of Mr. Roger McPherson as joint Company Secretary on an interim basis. Roger has more than 25 years' experience in senior finance roles in a wide variety of industries. His early career included working with a Chartered Accounting practice and two years with the Australian Taxation Office. In the past, Roger was CFO and Company Secretary for a number of SMEs both listed and unlisted including Bio- Gene, Patrys Limited, TPI Enterprises Ltd. and eChoice Home Loans. In these roles he was responsible for all financial affairs and corporate administration as well as assisting in investor relations activities. He has over 20 years of biotechnology and pharmaceutical experience. In addition to his role with Bio-Gene, Roger also provides CFO services to other unlisted entities.공시 • Oct 02Bio-Gene Technology Limited, Annual General Meeting, Nov 23, 2023Bio-Gene Technology Limited, Annual General Meeting, Nov 23, 2023, at 11:01 AUS Eastern Standard Time.New Risk • Sep 10New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 5.4% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$3.3m free cash flow). Earnings have declined by 7.4% per year over the past 5 years. Revenue is less than US$1m (AU$149k revenue, or US$95k). Minor Risks Shareholders have been diluted in the past year (5.4% increase in shares outstanding). Market cap is less than US$100m (AU$17.6m market cap, or US$11.2m).New Risk • Aug 01New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -AU$3.3m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$3.3m free cash flow). Share price has been highly volatile over the past 3 months (17% average weekly change). Earnings have declined by 7.4% per year over the past 5 years. Revenue is less than US$1m (AU$681k revenue, or US$450k). Market cap is less than US$10m (AU$15.1m market cap, or US$10.00m).Reported Earnings • Aug 01Full year 2023 earnings released: AU$0.018 loss per share (vs AU$0.019 loss in FY 2022)Full year 2023 results: AU$0.018 loss per share. Net loss: AU$3.10m (loss widened 6.2% from FY 2022).공시 • Jul 28+ 1 more updateBio-Gene Technology Limited Announces Managing Director ChangesBio-Gene Technology Limited announced the following executive changes: Mr. Tim Grogan has been appointed Managing Director, effective from 28th August 2023. Mr. Richard Jagger formally resigns as current Managing Director to transition to a new advisory role focused on stakeholder management of Bio-Gene's existing and future development partnerships at the end of September. Tim brings more than 30 years' experience and expertise to Bio-Gene, with a successful track record of delivering growth in the agtech, food and human health sectors. Tim has deep multi-disciplinary experience in the management of new product development, commercialisation, capital raising and corporate governance. As a hands-on leader, Tim has held several key executive roles, specialising in product development and expanding business partnerships. As CEO of SIRA Pty Ltd, Tim led the commercial development of technologies to produce new types of healthier sugar. Prior to this, Tim was the CEO of Dimerix BioScience Pty Ltd, where he managed the development of a novel treatment for diabetic nephropathy and the company completed three substantial pharmaceutical partnering deals within 12 months and significantly expanded its investor base. Tim also has extensive listed company experience, including with pharmaceutical development company, Starpharma, where he worked to steer it through the IPO process and establishing several commercial relationships globally. Most recently, Tim has been consulting to companies in the health and medical technology sectors in Australia, providing strategic, government and regulatory advice. Tim holds a Bachelor of Law and a Bachelor of Science, majoring in chemistry, from the University of Melbourne.New Risk • Jun 23New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: AU$14.3m (US$9.58m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Earnings have declined by 4.6% per year over the past 5 years. Revenue is less than US$1m (AU$97k revenue, or US$65k). Market cap is less than US$10m (AU$14.3m market cap, or US$9.58m).공시 • May 12Bio-Gene Technology Limited Announces Changes to the BoardBio-Gene Technology Limited announced the following changes to the Board and management: Due to significantly increased commitments associated with his other roles, Mr. Robert Klupacs has advised the Board that he will be retiring from the Board effective 31 July 2023. Before that time he will continue to act as Chair of the Company, and will be heavily involved in strategic negotiations for the company alongside the Bio- Gene management team. Robert joined Bio-Gene in 2015 as CEO and lead the Company to IPO in 2017, before becoming a Non-Executive Director in January 2018. Robert became Chair of the Company in November 2019. The Company also announces that Mr. Alex Ding and Mr. Chris Ramsay will join the Bio-Gene Board, effective immediately. Alex Ding was a partner at two leading Australian law firms, and is a recognised expert in mergers and acquisitions, capital markets, and general corporate and governance law. He has advised many large ASX, LSE and US listed companies, foreign government controlled entities and substantial private companies and funds on acquisitions, divestments, corporate finance transactions, joint venture arrangements, restructurings, corporate governance and disputes strategy. He has been named on The Best Lawyers in Australia list. Christopher Ramsay has over 30 years experience in the agricultural sector across business development, marketing and broader agronomy. He has held leadership roles in BASF and Nufarm among others, operating in both technical and managerial roles. Chris brings with him significant experience across customer engagement and product marketing and has a history of partnership development and sourcing after having spent the earlier years of his career in technical agricultural roles. Chris currently acts as non-executive director of North West Phosphate, a phosphate exploration and production business and principal director of a boutique agribusiness consulting firm. Chris holds a BSc (Honours) in Rural Sciences and a GradDip in Agribusiness.Reported Earnings • Feb 24First half 2023 earnings released: AU$0.012 loss per share (vs AU$0.01 loss in 1H 2022)First half 2023 results: AU$0.012 loss per share (further deteriorated from AU$0.01 loss in 1H 2022). Net loss: AU$1.97m (loss widened 37% from 1H 2022). Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has fallen by 17% per year, which means it is performing significantly worse than earnings.공시 • Dec 01Bio-Gene Technology Limited Submits Application to Secure Additional IP for QcidetmBio-Gene Technology Limited announced the filing of an application for PBR of several Eucalyptus cloeziana varieties containing high levels of tasmanone - the insecticidal ingredient in Qcide oil. This is an important milestone in Bio-Gene's Qcide tree improvement program which will significantly add to the value of the Company's technology. The extended period offered by these rights provides protection for the genetic material which improves both the yield and quality of Qcide oil, which translates to advantages for its commercial collaborators as they develop new and novel products for the marketplace. The ongoing development of IP for the company's technology platform is a key component of the company's strategic plan to deliver value to its customers and shareholders.Board Change • Nov 16No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Non-Executive Director Andrew Guthrie was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.공시 • Sep 30Bio-Gene Technology Limited, Annual General Meeting, Nov 18, 2022Bio-Gene Technology Limited, Annual General Meeting, Nov 18, 2022, at 11:00 AUS Eastern Standard Time.Reported Earnings • Aug 18Full year 2022 earnings released: AU$0.019 loss per share (vs AU$0.017 loss in FY 2021)Full year 2022 results: AU$0.019 loss per share (down from AU$0.017 loss in FY 2021). Net loss: AU$2.91m (loss widened 22% from FY 2021). Over the last 3 years on average, earnings per share has fallen by 5% per year whereas the company’s share price has fallen by 1% per year.Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Non-Executive Director Andrew Guthrie was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.공시 • Mar 07Bio-Gene Technology Limited Announces Positive Stored Grain Pest ResultsBio-Gene Technology Limited announced positive results from the latest stored grain trial, showing efficacy over the targeted 9-month protection period. In September 2020, Bio-Gene announced the successful identification of a lead Flavocide combination treatment to be taken to field testing as part of a 9-month efficacy study in collaboration with its research and commercial partners. The 9-month combination treatment study is stage 3 of the collaboration program. This stage of the program was designed to demonstrate the effectiveness of the combination treatment to control five of the key stored grain pests, being the Lesser grain borer, Flour beetle, Saw-toothed grain beetle, Flat grain beetle and Rice weevil. The 3-month interim results were announced during 2021 and showed that the combination treatments were providing control of all of five key pests at this intermediate stage. Assessments were subsequently undertaken at 6 and 9 months after treatment. Results showed that the combination treatments provided complete control of non-resistant strains of all species, as well as control of resistant strains of three of the five target species, for the full 9-month testing period. Resistant strains of two of the five target species were controlled for a 3-month period, indicating that higher rates of application or alternative combination treatments would be required to control these highly resistant strains for a longer period. The Department of Agriculture and Fisheries, Queensland (DAF) also recently reported on testing of Flavocide against Lesser grain borer in other grain types namely maize and barley. The results showed that Flavocide provided similar levels of control to that obtained in wheat. Currently there is no single chemistry that controls all major pests that impact stored grain. The incidence of pest resistance is rising in Australia, and around the world. In some cases, losses of up to 70% of grain in storage have been attributed to pests1. Flavocide has the potential to create formulations that will enable control of the full range of pests including pests resistant to other classes of chemistry. The introduction of products with a novel Mode of Action, such as Flavocide, is critical for pest management in stored grain to reduce the potential of increased insecticide resistance in the future.분석 기사 • Feb 22We're Hopeful That Bio-Gene Technology (ASX:BGT) Will Use Its Cash WiselyWe can readily understand why investors are attracted to unprofitable companies. For example, although...Reported Earnings • Feb 21First half 2022 earnings: EPS exceeds analyst expectations while revenues lag behindFirst half 2022 results: AU$0.01 loss per share (vs AU$0.01 loss in 1H 2021). Net loss: AU$1.44m (loss widened 8.1% from 1H 2021). Revenue missed analyst estimates by 95%. Earnings per share (EPS) exceeded analyst estimates by 75%. Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has increased by 28% per year, which means it is tracking significantly ahead of earnings growth.공시 • Feb 07Bio-Gene Technology Limited Appoints Sarah Driessens as Head of Regulatory AffairsBio-Gene Technology Limited announced the appointment of Sarah Driessens to the role of Head of Regulatory Affairs with global responsibilities. Sarah has recently relocated to Australia, after previously being based in Brussels, Belgium. Sarah has worked for over 13 years with Monsanto. Her main areas of focus were product registration for agricultural and consumer products across major geographic jurisdictions. Sarah will commence with Bio-Gene in late February 2022.공시 • Dec 17Bio-Gene Technology Limited announced that it has received AUD 3.04775 million in fundingOn December 17, 2021, Bio-Gene Technology Limited closed the transaction. The company has amended the terms of the transaction. The company has issued 17,927,941 fully paid shares at a price of AUD 0.17 per share for the gross proceeds of AUD 3,047,750. The company issued shares without disclosure to investors under Part 6D.2 of the Act.공시 • Dec 09Bio-Gene Technology Limited announced that it expects to receive AUD 3.21931 million in fundingBio-Gene Technology Limited announced a private placement of 18,937,119 common shares at a price of AUD 0.17 per share for the gross proceeds of AUD 3,200,000 on December 9, 2021. The transaction will include participation from directors of the company, new and existing sophisticated and professional investors. The transaction is subject to approval to Shareholder Approval. The transaction is expected to be closed by December 19, 2021.분석 기사 • Oct 25Here's Why We're Not Too Worried About Bio-Gene Technology's (ASX:BGT) Cash Burn SituationWe can readily understand why investors are attracted to unprofitable companies. For example, although...Reported Earnings • Aug 27Full year 2021 earnings released: AU$0.017 loss per share (vs AU$0.016 loss in FY 2020)Full year 2021 results: Net loss: AU$2.40m (loss widened 24% from FY 2020). Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth.Breakeven Date Change • Jul 04Forecast to breakeven in 2024The analyst covering Bio-Gene Technology expects the company to break even for the first time. New forecast suggests the company will make a profit of AU$1.50m in 2024. Average annual earnings growth of 78% is required to achieve expected profit on schedule.분석 기사 • Jun 20Here's Why We're Not At All Concerned With Bio-Gene Technology's (ASX:BGT) Cash Burn SituationEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...분석 기사 • Apr 28Bio-Gene Technology Limited (ASX:BGT) Is Expected To Breakeven In The Near FutureBio-Gene Technology Limited ( ASX:BGT ) is possibly approaching a major achievement in its business, so we would like...공시 • Feb 25Bio-Gene Technology Limited Appoints James Joughin as Non-Executive Director of the Company and Chairman of Audit and Risk Committee, Effective 1 March 2021Bio-Gene Technology Limited announced the appointment of Mr. James Joughin as a Non-executive Director of the Company and Chairman of Audit and Risk Committee. James is a highly experienced ASX listed and private company Director. He is currently the Non-Executive Chairman at Spirit Technology Solutions Ltd. and a Non-Executive Director at Mydeal.com.au Ltd, Viridian Financial Group Ltd. and Melbourne Institute of Technology Pty Ltd. Mr. Joughin's appointment is effective from 1 March 2021.공시 • Feb 24Bio-Gene Technology Limited Announces Flavocide MoA Studies Confirm Target Site of ActivityBio-Gene Technology Limited announced the successful completion of additional mode of action ("MoA") studies which confirm a definitive target site of Flavocide in insects. These results represent a key milestone in the development of Bio-Gene's proprietary insecticide technology. Previous studies demonstrated that Flavocide has a MoA quite different to other known insecticide classes, with activity located within a region of the insect not targeted by other chemistry. These results were supported by testing on populations of pests resistant to other classes of chemistry, where Bio-Gene's technology was shown to control those pests. This provided Bio-Gene with a candidate target site within insects with which to conduct these more definitive studies. This latest series of studies undertaken by the specialist contract research company Pacific Discovery Services - sought to identify a definitive target site using more advanced and directed methodology. This testing resulted in a response to Flavocide that was identical to that found in previous studies but was more clearly expressed, therefore confirming this as a definitive target site of Flavocide. Categorically identifying the site of the unique MoA for Flavocide and QcideTM will enable increased engagement with both industry experts and commercial companies who are looking to find new chemistry to develop effective commercial products. These results also provide critical information that will be important in creating validation data which will ultimately enable Bio-Gene to apply for a "new class of chemistry" with IRAC (Insecticide Resistance Action Committee), a specialist technical group of the global industry association CropLife. A unique classification means Flavocide, and other beta-triketone-based insecticides such as Bio-Gene's Qcide, would be incorporated into current and future Resistance Management Programs developed by the industry for specific pest/crop situations.Reported Earnings • Feb 20First half 2021 earnings released: AU$0.01 loss per share (vs AU$0.009 loss in 1H 2020)First half 2021 results: Net loss: AU$1.33m (loss widened 25% from 1H 2020). Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.공시 • Jan 22Bio-Gene Technology Limited Announces Positive Preliminary Results from Aquatic (Rainbow Trout) and Avian (Mallard Duck) Eco-Toxicity StudiesBio-Gene Technology Limited announced positive preliminary results from aquatic (Rainbow Trout) and avian (Mallard Duck) eco-toxicity studies. These studies were undertaken with technical grade flavesone, the active constituent contained in Flavocide, and contribute strongly to the data package that will support regulatory approval and commercialisation. This most recent study was performed on Rainbow Trout (Oncorhynchus mykiss) under the Organisation for Economic Co-Operation and Development guidelines for fish acute toxicity testing. The results of the study indicated that based on a five-step scale used to classify pesticides into toxicity categories for terrestrial and aquatic organisms, Flavocide was classed as `practically non-toxic' and therefore falls within the lowest toxicity category for this species. The study represents a continuation of the recent testing of Flavocide on other non-target species in aquatic eco-systems announced in June 2020 that included data on Poecilia reticulata (Guppy), Daphnia magna (water flea) and Pseudokirchneriella subcapitata (freshwater algae). Overall results showed that no adverse effects were observed in any species from exposure to Flavocide at the doses tested, which included the highest doses able to be achieved within the limitation of water solubility of the compound. Rainbow Trout is a key target temperate species used to indicate the environmental impact from the use of a pesticide in an aquatic environment. Acute toxicity studies are key to further profiling and understanding the potential hazards posed by products containing flavesone when released into the environment, with particular relevance to outdoor uses such as for mosquito control and crop protection. Mallard Duck (Anas platyrhynchos) represents a key aquatic avian species to assess the impact from the introduction of an insecticide to the environment. This study positively builds on the previous study undertaken on a land-based avian species (Japanese Quail) and aims to further profile the effects of Flavocide on different avian species that occupy both terrestrial and aquatic habitats. These studies compliment the aquatic species studies and are also pivotal to further profiling and understanding the safety profile of products containing flavesone when released into the environment. The studies involved administering Flavocide to birds at a range of dose levels to accurately determine the acute oral toxicity effects. Based on a five-step scale used to classify pesticides into toxicity categories for terrestrial and aquatic organisms, the trial determined Flavocide technical was `moderately toxic' and therefore falls into the middle toxicity category for this species. A moderately toxic classification is well within the range of currently registered insecticides and thus a positive outcome in terms of expected non-target impact assessment for registration. These preliminary data on Rainbow Trout and Mallard Duck, together with eco-toxicity data recently obtained on other non-target species, would indicate that Flavocide would likely have minimal impact on non-target species in both aquatic and terrestrial eco-systems. These results continue to provide evidence to support a strong safety profile for products containing Flavocide which may inadvertently encounter non-target species in the environment. Most importantly, the information will also aid product registrations and support promotion of Bio-Gene products to potential commercial partners with an interest in commercialising the company's technology and products.분석 기사 • Jan 11What We Learned About Bio-Gene Technology's (ASX:BGT) CEO CompensationRichard Jagger has been the CEO of Bio-Gene Technology Limited ( ASX:BGT ) since 2018, and this article will examine...공시 • Dec 19Bio-Gene Technology Limited Appoints Peter Beetham as Non- Executive Director, Effective from 21 December 2020Bio-Gene Technology Limited announced the appointment of Dr. Peter Beetham as a Non- executive Director of the Company. Dr. Beetham is the co-founder and Chief Executive Officer of Cibus Global, LLC (Cibus). Dr. Beetham's appointment is effective from 21 December 2020. Dr. Beetham has over 30 years of experience in the bio-agriculture community, with a passion for moving technology to commercial application. He was employed by the Victorian Department of Agriculture and Rural Affairs (DARA) in Australia from 1985 to 1992, serving as a Scientific Officer based at the Plant Research Institute (PRI), working with research groups throughout Southeast Asia and the South Pacific.공시 • Nov 26Bio-Gene Technology Limited Announces Changes of DirectorsBio-Gene Technology Limited announced in the Results of Meeting, Non-executive Chairman Don Brumley and Non-executive Director Kevin Rumble were not re-elected by shareholders at the 2020 Annual General Meeting (AGM) and have therefore retired as Directors of the Company effective at the close of the 2020 AGM. The Board is, and has been, on a path to make some changes that will result in the company benefitting from additional non-executive expertise. The Company is currently progressing discussions and the due diligence process with several potential candidates. Don, who led the Company to and through the IPO process and Kevin, whose passion as the founder of the Company has strongly supported the progress achieved to date. The remaining Directors have also resolved that Non-executive Director Robert Klupacs will act as the Company's Chairman in an interim capacity until the process of appointing new non-executive directors is concluded. The Company will make further announcements in that regard in due course.공시 • Jun 19Bio-Gene Technology Limited has completed a Follow-on Equity Offering in the amount of AUD 0.427998 million.Bio-Gene Technology Limited has completed a Follow-on Equity Offering in the amount of AUD 0.427998 million. Security Name: Shares Security Type: Common Stock Securities Offered: 2,761,276 Price\Range: AUD 0.155매출 및 비용 세부 내역Bio-Gene Technology가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이ASX:BGT 매출, 비용 및 순이익 (AUD Millions)날짜매출순이익일반관리비연구개발비31 Dec 250-32230 Sep 250-31230 Jun 250-31131 Mar 250-22131 Dec 240-22130 Sep 240-22130 Jun 240-22131 Mar 240-32131 Dec 230-32130 Sep 230-31230 Jun 230-31231 Mar 230-31231 Dec 220-31230 Sep 220-31230 Jun 220-31231 Mar 220-31231 Dec 210-31230 Sep 210-21230 Jun 210-21231 Mar 210-21231 Dec 200-21230 Sep 200-21130 Jun 200-21131 Mar 200-21131 Dec 190-21130 Sep 190-21130 Jun 190-21131 Mar 190-21131 Dec 181-31130 Sep 180-31130 Jun 180-31131 Mar 180-31131 Dec 170-21130 Sep 170-21130 Jun 170-10130 Jun 160000양질의 수익: BGT 은(는) 현재 수익성이 없습니다.이익 마진 증가: BGT는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: BGT는 수익성이 없지만 지난 5년 동안 연평균 0.3%의 속도로 손실을 줄였습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 BGT의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: BGT은 수익성이 없어 지난 해 수익 성장률을 Chemicals 업계(4.7%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: BGT는 현재 수익성이 없으므로 자본 수익률이 음수(-216.01%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YMaterials 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/22 00:06종가2026/05/21 00:00수익2025/12/31연간 수익2025/06/30데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Bio-Gene Technology Limited는 1명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Tom WaitePAC Partners Securities Pty. Ltd.
Reported Earnings • Aug 01Full year 2023 earnings released: AU$0.018 loss per share (vs AU$0.019 loss in FY 2022)Full year 2023 results: AU$0.018 loss per share. Net loss: AU$3.10m (loss widened 6.2% from FY 2022).
Reported Earnings • Feb 24First half 2023 earnings released: AU$0.012 loss per share (vs AU$0.01 loss in 1H 2022)First half 2023 results: AU$0.012 loss per share (further deteriorated from AU$0.01 loss in 1H 2022). Net loss: AU$1.97m (loss widened 37% from 1H 2022). Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has fallen by 17% per year, which means it is performing significantly worse than earnings.
Reported Earnings • Aug 18Full year 2022 earnings released: AU$0.019 loss per share (vs AU$0.017 loss in FY 2021)Full year 2022 results: AU$0.019 loss per share (down from AU$0.017 loss in FY 2021). Net loss: AU$2.91m (loss widened 22% from FY 2021). Over the last 3 years on average, earnings per share has fallen by 5% per year whereas the company’s share price has fallen by 1% per year.
Reported Earnings • Feb 21First half 2022 earnings: EPS exceeds analyst expectations while revenues lag behindFirst half 2022 results: AU$0.01 loss per share (vs AU$0.01 loss in 1H 2021). Net loss: AU$1.44m (loss widened 8.1% from 1H 2021). Revenue missed analyst estimates by 95%. Earnings per share (EPS) exceeded analyst estimates by 75%. Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has increased by 28% per year, which means it is tracking significantly ahead of earnings growth.
Reported Earnings • Aug 27Full year 2021 earnings released: AU$0.017 loss per share (vs AU$0.016 loss in FY 2020)Full year 2021 results: Net loss: AU$2.40m (loss widened 24% from FY 2020). Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Feb 20First half 2021 earnings released: AU$0.01 loss per share (vs AU$0.009 loss in 1H 2020)First half 2021 results: Net loss: AU$1.33m (loss widened 25% from 1H 2020). Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.
New Risk • Jan 22New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 14% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$2.5m free cash flow). Earnings have declined by 2.8% per year over the past 5 years. Shareholders have been substantially diluted in the past year (51% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (AU$10.4m market cap, or US$7.06m). Minor Risk Share price has been volatile over the past 3 months (14% average weekly change).
Board Change • Jan 05No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. MD, CEO & Director Tim Grogan was the last director to join the board, commencing their role in 2023. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
New Risk • Dec 17New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Australian stocks, typically moving 18% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$2.5m free cash flow). Share price has been highly volatile over the past 3 months (18% average weekly change). Earnings have declined by 2.8% per year over the past 5 years. Shareholders have been substantially diluted in the past year (51% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (AU$7.02m market cap, or US$4.66m).
공시 • Sep 30Bio-Gene Technology Limited, Annual General Meeting, Nov 19, 2025Bio-Gene Technology Limited, Annual General Meeting, Nov 19, 2025.
New Risk • Sep 19New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 15% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$2.5m free cash flow). Earnings have declined by 2.8% per year over the past 5 years. Shareholders have been substantially diluted in the past year (51% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (AU$9.15m market cap, or US$6.05m). Minor Risk Share price has been volatile over the past 3 months (15% average weekly change).
New Risk • Aug 27New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -AU$2.5m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$2.5m free cash flow). Earnings have declined by 2.8% per year over the past 5 years. Shareholders have been substantially diluted in the past year (51% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (AU$6.71m market cap, or US$4.35m).
New Risk • Jul 04New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 32% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 6.1% per year over the past 5 years. Shareholders have been substantially diluted in the past year (32% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (AU$4.80m market cap, or US$3.15m). Minor Risk Share price has been volatile over the past 3 months (14% average weekly change).
공시 • May 05+ 1 more updateBio-Gene Technology Limited has filed a Follow-on Equity Offering in the amount of AUD 0.69 million.Bio-Gene Technology Limited has filed a Follow-on Equity Offering in the amount of AUD 0.69 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 30,000,000 Price\Range: AUD 0.023 Security Features: Attached Options
New Risk • Jan 29New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Australian stocks, typically moving 29% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$2.8m free cash flow). Share price has been highly volatile over the past 3 months (29% average weekly change). Earnings have declined by 9.0% per year over the past 5 years. Revenue is less than US$1m (AU$18k revenue, or US$11k). Market cap is less than US$10m (AU$10.7m market cap, or US$6.65m).
New Risk • Dec 17New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$2.8m free cash flow). Earnings have declined by 9.0% per year over the past 5 years. Revenue is less than US$1m (AU$18k revenue, or US$12k). Market cap is less than US$10m (AU$7.65m market cap, or US$4.87m). Minor Risk Share price has been volatile over the past 3 months (12% average weekly change).
공시 • Oct 04Bio-Gene Technology Limited, Annual General Meeting, Nov 29, 2024Bio-Gene Technology Limited, Annual General Meeting, Nov 29, 2024.
New Risk • May 06New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Australian stocks, typically moving 18% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (18% average weekly change). Earnings have declined by 9.6% per year over the past 5 years. Revenue is less than US$1m (AU$168k revenue, or US$111k). Market cap is less than US$10m (AU$13.9m market cap, or US$9.19m). Minor Risk Shareholders have been diluted in the past year (13% increase in shares outstanding).
New Risk • Feb 16New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 7.4% per year over the past 5 years. Revenue is less than US$1m (AU$149k revenue, or US$97k). Market cap is less than US$10m (AU$11.1m market cap, or US$7.22m). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Shareholders have been diluted in the past year (13% increase in shares outstanding).
New Risk • Dec 12New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 7.4% per year over the past 5 years. Revenue is less than US$1m (AU$149k revenue, or US$98k). Market cap is less than US$10m (AU$12.1m market cap, or US$7.96m). Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Shareholders have been diluted in the past year (13% increase in shares outstanding).
공시 • Nov 23Bio-Gene Technology Limited Approves the Election of Alex Ding as DirectorBio-Gene Technology Limited at its AGM held on November 23, 2023, approved the election of Mr. Alex Ding as a Director.
공시 • Nov 15+ 1 more updateBio-Gene Technology Limited Announces Resignation of Rodrigo Valencia as Joint CFOBio-Gene Technology Limited announced the resignation of Mr. Rodrigo Valencia as joint CFO and Company Secretary effective immediately. Mr. Roger McPherson will remain with Bio-Gene, on an interim basis, as the sole CFO and Company Secretary, while the Company seeks a suitable permanent replacement.
공시 • Oct 30Bio-Gene Technology Limited Announces the Appointment of Roger Mcpherson as Joint Company SecretaryBio-Gene Technology Limited announced the appointment of Mr. Roger McPherson as joint Company Secretary on an interim basis. Roger has more than 25 years' experience in senior finance roles in a wide variety of industries. His early career included working with a Chartered Accounting practice and two years with the Australian Taxation Office. In the past, Roger was CFO and Company Secretary for a number of SMEs both listed and unlisted including Bio- Gene, Patrys Limited, TPI Enterprises Ltd. and eChoice Home Loans. In these roles he was responsible for all financial affairs and corporate administration as well as assisting in investor relations activities. He has over 20 years of biotechnology and pharmaceutical experience. In addition to his role with Bio-Gene, Roger also provides CFO services to other unlisted entities.
공시 • Oct 02Bio-Gene Technology Limited, Annual General Meeting, Nov 23, 2023Bio-Gene Technology Limited, Annual General Meeting, Nov 23, 2023, at 11:01 AUS Eastern Standard Time.
New Risk • Sep 10New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 5.4% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$3.3m free cash flow). Earnings have declined by 7.4% per year over the past 5 years. Revenue is less than US$1m (AU$149k revenue, or US$95k). Minor Risks Shareholders have been diluted in the past year (5.4% increase in shares outstanding). Market cap is less than US$100m (AU$17.6m market cap, or US$11.2m).
New Risk • Aug 01New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -AU$3.3m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$3.3m free cash flow). Share price has been highly volatile over the past 3 months (17% average weekly change). Earnings have declined by 7.4% per year over the past 5 years. Revenue is less than US$1m (AU$681k revenue, or US$450k). Market cap is less than US$10m (AU$15.1m market cap, or US$10.00m).
Reported Earnings • Aug 01Full year 2023 earnings released: AU$0.018 loss per share (vs AU$0.019 loss in FY 2022)Full year 2023 results: AU$0.018 loss per share. Net loss: AU$3.10m (loss widened 6.2% from FY 2022).
공시 • Jul 28+ 1 more updateBio-Gene Technology Limited Announces Managing Director ChangesBio-Gene Technology Limited announced the following executive changes: Mr. Tim Grogan has been appointed Managing Director, effective from 28th August 2023. Mr. Richard Jagger formally resigns as current Managing Director to transition to a new advisory role focused on stakeholder management of Bio-Gene's existing and future development partnerships at the end of September. Tim brings more than 30 years' experience and expertise to Bio-Gene, with a successful track record of delivering growth in the agtech, food and human health sectors. Tim has deep multi-disciplinary experience in the management of new product development, commercialisation, capital raising and corporate governance. As a hands-on leader, Tim has held several key executive roles, specialising in product development and expanding business partnerships. As CEO of SIRA Pty Ltd, Tim led the commercial development of technologies to produce new types of healthier sugar. Prior to this, Tim was the CEO of Dimerix BioScience Pty Ltd, where he managed the development of a novel treatment for diabetic nephropathy and the company completed three substantial pharmaceutical partnering deals within 12 months and significantly expanded its investor base. Tim also has extensive listed company experience, including with pharmaceutical development company, Starpharma, where he worked to steer it through the IPO process and establishing several commercial relationships globally. Most recently, Tim has been consulting to companies in the health and medical technology sectors in Australia, providing strategic, government and regulatory advice. Tim holds a Bachelor of Law and a Bachelor of Science, majoring in chemistry, from the University of Melbourne.
New Risk • Jun 23New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: AU$14.3m (US$9.58m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Earnings have declined by 4.6% per year over the past 5 years. Revenue is less than US$1m (AU$97k revenue, or US$65k). Market cap is less than US$10m (AU$14.3m market cap, or US$9.58m).
공시 • May 12Bio-Gene Technology Limited Announces Changes to the BoardBio-Gene Technology Limited announced the following changes to the Board and management: Due to significantly increased commitments associated with his other roles, Mr. Robert Klupacs has advised the Board that he will be retiring from the Board effective 31 July 2023. Before that time he will continue to act as Chair of the Company, and will be heavily involved in strategic negotiations for the company alongside the Bio- Gene management team. Robert joined Bio-Gene in 2015 as CEO and lead the Company to IPO in 2017, before becoming a Non-Executive Director in January 2018. Robert became Chair of the Company in November 2019. The Company also announces that Mr. Alex Ding and Mr. Chris Ramsay will join the Bio-Gene Board, effective immediately. Alex Ding was a partner at two leading Australian law firms, and is a recognised expert in mergers and acquisitions, capital markets, and general corporate and governance law. He has advised many large ASX, LSE and US listed companies, foreign government controlled entities and substantial private companies and funds on acquisitions, divestments, corporate finance transactions, joint venture arrangements, restructurings, corporate governance and disputes strategy. He has been named on The Best Lawyers in Australia list. Christopher Ramsay has over 30 years experience in the agricultural sector across business development, marketing and broader agronomy. He has held leadership roles in BASF and Nufarm among others, operating in both technical and managerial roles. Chris brings with him significant experience across customer engagement and product marketing and has a history of partnership development and sourcing after having spent the earlier years of his career in technical agricultural roles. Chris currently acts as non-executive director of North West Phosphate, a phosphate exploration and production business and principal director of a boutique agribusiness consulting firm. Chris holds a BSc (Honours) in Rural Sciences and a GradDip in Agribusiness.
Reported Earnings • Feb 24First half 2023 earnings released: AU$0.012 loss per share (vs AU$0.01 loss in 1H 2022)First half 2023 results: AU$0.012 loss per share (further deteriorated from AU$0.01 loss in 1H 2022). Net loss: AU$1.97m (loss widened 37% from 1H 2022). Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has fallen by 17% per year, which means it is performing significantly worse than earnings.
공시 • Dec 01Bio-Gene Technology Limited Submits Application to Secure Additional IP for QcidetmBio-Gene Technology Limited announced the filing of an application for PBR of several Eucalyptus cloeziana varieties containing high levels of tasmanone - the insecticidal ingredient in Qcide oil. This is an important milestone in Bio-Gene's Qcide tree improvement program which will significantly add to the value of the Company's technology. The extended period offered by these rights provides protection for the genetic material which improves both the yield and quality of Qcide oil, which translates to advantages for its commercial collaborators as they develop new and novel products for the marketplace. The ongoing development of IP for the company's technology platform is a key component of the company's strategic plan to deliver value to its customers and shareholders.
Board Change • Nov 16No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Non-Executive Director Andrew Guthrie was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
공시 • Sep 30Bio-Gene Technology Limited, Annual General Meeting, Nov 18, 2022Bio-Gene Technology Limited, Annual General Meeting, Nov 18, 2022, at 11:00 AUS Eastern Standard Time.
Reported Earnings • Aug 18Full year 2022 earnings released: AU$0.019 loss per share (vs AU$0.017 loss in FY 2021)Full year 2022 results: AU$0.019 loss per share (down from AU$0.017 loss in FY 2021). Net loss: AU$2.91m (loss widened 22% from FY 2021). Over the last 3 years on average, earnings per share has fallen by 5% per year whereas the company’s share price has fallen by 1% per year.
Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Non-Executive Director Andrew Guthrie was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
공시 • Mar 07Bio-Gene Technology Limited Announces Positive Stored Grain Pest ResultsBio-Gene Technology Limited announced positive results from the latest stored grain trial, showing efficacy over the targeted 9-month protection period. In September 2020, Bio-Gene announced the successful identification of a lead Flavocide combination treatment to be taken to field testing as part of a 9-month efficacy study in collaboration with its research and commercial partners. The 9-month combination treatment study is stage 3 of the collaboration program. This stage of the program was designed to demonstrate the effectiveness of the combination treatment to control five of the key stored grain pests, being the Lesser grain borer, Flour beetle, Saw-toothed grain beetle, Flat grain beetle and Rice weevil. The 3-month interim results were announced during 2021 and showed that the combination treatments were providing control of all of five key pests at this intermediate stage. Assessments were subsequently undertaken at 6 and 9 months after treatment. Results showed that the combination treatments provided complete control of non-resistant strains of all species, as well as control of resistant strains of three of the five target species, for the full 9-month testing period. Resistant strains of two of the five target species were controlled for a 3-month period, indicating that higher rates of application or alternative combination treatments would be required to control these highly resistant strains for a longer period. The Department of Agriculture and Fisheries, Queensland (DAF) also recently reported on testing of Flavocide against Lesser grain borer in other grain types namely maize and barley. The results showed that Flavocide provided similar levels of control to that obtained in wheat. Currently there is no single chemistry that controls all major pests that impact stored grain. The incidence of pest resistance is rising in Australia, and around the world. In some cases, losses of up to 70% of grain in storage have been attributed to pests1. Flavocide has the potential to create formulations that will enable control of the full range of pests including pests resistant to other classes of chemistry. The introduction of products with a novel Mode of Action, such as Flavocide, is critical for pest management in stored grain to reduce the potential of increased insecticide resistance in the future.
분석 기사 • Feb 22We're Hopeful That Bio-Gene Technology (ASX:BGT) Will Use Its Cash WiselyWe can readily understand why investors are attracted to unprofitable companies. For example, although...
Reported Earnings • Feb 21First half 2022 earnings: EPS exceeds analyst expectations while revenues lag behindFirst half 2022 results: AU$0.01 loss per share (vs AU$0.01 loss in 1H 2021). Net loss: AU$1.44m (loss widened 8.1% from 1H 2021). Revenue missed analyst estimates by 95%. Earnings per share (EPS) exceeded analyst estimates by 75%. Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has increased by 28% per year, which means it is tracking significantly ahead of earnings growth.
공시 • Feb 07Bio-Gene Technology Limited Appoints Sarah Driessens as Head of Regulatory AffairsBio-Gene Technology Limited announced the appointment of Sarah Driessens to the role of Head of Regulatory Affairs with global responsibilities. Sarah has recently relocated to Australia, after previously being based in Brussels, Belgium. Sarah has worked for over 13 years with Monsanto. Her main areas of focus were product registration for agricultural and consumer products across major geographic jurisdictions. Sarah will commence with Bio-Gene in late February 2022.
공시 • Dec 17Bio-Gene Technology Limited announced that it has received AUD 3.04775 million in fundingOn December 17, 2021, Bio-Gene Technology Limited closed the transaction. The company has amended the terms of the transaction. The company has issued 17,927,941 fully paid shares at a price of AUD 0.17 per share for the gross proceeds of AUD 3,047,750. The company issued shares without disclosure to investors under Part 6D.2 of the Act.
공시 • Dec 09Bio-Gene Technology Limited announced that it expects to receive AUD 3.21931 million in fundingBio-Gene Technology Limited announced a private placement of 18,937,119 common shares at a price of AUD 0.17 per share for the gross proceeds of AUD 3,200,000 on December 9, 2021. The transaction will include participation from directors of the company, new and existing sophisticated and professional investors. The transaction is subject to approval to Shareholder Approval. The transaction is expected to be closed by December 19, 2021.
분석 기사 • Oct 25Here's Why We're Not Too Worried About Bio-Gene Technology's (ASX:BGT) Cash Burn SituationWe can readily understand why investors are attracted to unprofitable companies. For example, although...
Reported Earnings • Aug 27Full year 2021 earnings released: AU$0.017 loss per share (vs AU$0.016 loss in FY 2020)Full year 2021 results: Net loss: AU$2.40m (loss widened 24% from FY 2020). Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth.
Breakeven Date Change • Jul 04Forecast to breakeven in 2024The analyst covering Bio-Gene Technology expects the company to break even for the first time. New forecast suggests the company will make a profit of AU$1.50m in 2024. Average annual earnings growth of 78% is required to achieve expected profit on schedule.
분석 기사 • Jun 20Here's Why We're Not At All Concerned With Bio-Gene Technology's (ASX:BGT) Cash Burn SituationEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
분석 기사 • Apr 28Bio-Gene Technology Limited (ASX:BGT) Is Expected To Breakeven In The Near FutureBio-Gene Technology Limited ( ASX:BGT ) is possibly approaching a major achievement in its business, so we would like...
공시 • Feb 25Bio-Gene Technology Limited Appoints James Joughin as Non-Executive Director of the Company and Chairman of Audit and Risk Committee, Effective 1 March 2021Bio-Gene Technology Limited announced the appointment of Mr. James Joughin as a Non-executive Director of the Company and Chairman of Audit and Risk Committee. James is a highly experienced ASX listed and private company Director. He is currently the Non-Executive Chairman at Spirit Technology Solutions Ltd. and a Non-Executive Director at Mydeal.com.au Ltd, Viridian Financial Group Ltd. and Melbourne Institute of Technology Pty Ltd. Mr. Joughin's appointment is effective from 1 March 2021.
공시 • Feb 24Bio-Gene Technology Limited Announces Flavocide MoA Studies Confirm Target Site of ActivityBio-Gene Technology Limited announced the successful completion of additional mode of action ("MoA") studies which confirm a definitive target site of Flavocide in insects. These results represent a key milestone in the development of Bio-Gene's proprietary insecticide technology. Previous studies demonstrated that Flavocide has a MoA quite different to other known insecticide classes, with activity located within a region of the insect not targeted by other chemistry. These results were supported by testing on populations of pests resistant to other classes of chemistry, where Bio-Gene's technology was shown to control those pests. This provided Bio-Gene with a candidate target site within insects with which to conduct these more definitive studies. This latest series of studies undertaken by the specialist contract research company Pacific Discovery Services - sought to identify a definitive target site using more advanced and directed methodology. This testing resulted in a response to Flavocide that was identical to that found in previous studies but was more clearly expressed, therefore confirming this as a definitive target site of Flavocide. Categorically identifying the site of the unique MoA for Flavocide and QcideTM will enable increased engagement with both industry experts and commercial companies who are looking to find new chemistry to develop effective commercial products. These results also provide critical information that will be important in creating validation data which will ultimately enable Bio-Gene to apply for a "new class of chemistry" with IRAC (Insecticide Resistance Action Committee), a specialist technical group of the global industry association CropLife. A unique classification means Flavocide, and other beta-triketone-based insecticides such as Bio-Gene's Qcide, would be incorporated into current and future Resistance Management Programs developed by the industry for specific pest/crop situations.
Reported Earnings • Feb 20First half 2021 earnings released: AU$0.01 loss per share (vs AU$0.009 loss in 1H 2020)First half 2021 results: Net loss: AU$1.33m (loss widened 25% from 1H 2020). Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.
공시 • Jan 22Bio-Gene Technology Limited Announces Positive Preliminary Results from Aquatic (Rainbow Trout) and Avian (Mallard Duck) Eco-Toxicity StudiesBio-Gene Technology Limited announced positive preliminary results from aquatic (Rainbow Trout) and avian (Mallard Duck) eco-toxicity studies. These studies were undertaken with technical grade flavesone, the active constituent contained in Flavocide, and contribute strongly to the data package that will support regulatory approval and commercialisation. This most recent study was performed on Rainbow Trout (Oncorhynchus mykiss) under the Organisation for Economic Co-Operation and Development guidelines for fish acute toxicity testing. The results of the study indicated that based on a five-step scale used to classify pesticides into toxicity categories for terrestrial and aquatic organisms, Flavocide was classed as `practically non-toxic' and therefore falls within the lowest toxicity category for this species. The study represents a continuation of the recent testing of Flavocide on other non-target species in aquatic eco-systems announced in June 2020 that included data on Poecilia reticulata (Guppy), Daphnia magna (water flea) and Pseudokirchneriella subcapitata (freshwater algae). Overall results showed that no adverse effects were observed in any species from exposure to Flavocide at the doses tested, which included the highest doses able to be achieved within the limitation of water solubility of the compound. Rainbow Trout is a key target temperate species used to indicate the environmental impact from the use of a pesticide in an aquatic environment. Acute toxicity studies are key to further profiling and understanding the potential hazards posed by products containing flavesone when released into the environment, with particular relevance to outdoor uses such as for mosquito control and crop protection. Mallard Duck (Anas platyrhynchos) represents a key aquatic avian species to assess the impact from the introduction of an insecticide to the environment. This study positively builds on the previous study undertaken on a land-based avian species (Japanese Quail) and aims to further profile the effects of Flavocide on different avian species that occupy both terrestrial and aquatic habitats. These studies compliment the aquatic species studies and are also pivotal to further profiling and understanding the safety profile of products containing flavesone when released into the environment. The studies involved administering Flavocide to birds at a range of dose levels to accurately determine the acute oral toxicity effects. Based on a five-step scale used to classify pesticides into toxicity categories for terrestrial and aquatic organisms, the trial determined Flavocide technical was `moderately toxic' and therefore falls into the middle toxicity category for this species. A moderately toxic classification is well within the range of currently registered insecticides and thus a positive outcome in terms of expected non-target impact assessment for registration. These preliminary data on Rainbow Trout and Mallard Duck, together with eco-toxicity data recently obtained on other non-target species, would indicate that Flavocide would likely have minimal impact on non-target species in both aquatic and terrestrial eco-systems. These results continue to provide evidence to support a strong safety profile for products containing Flavocide which may inadvertently encounter non-target species in the environment. Most importantly, the information will also aid product registrations and support promotion of Bio-Gene products to potential commercial partners with an interest in commercialising the company's technology and products.
분석 기사 • Jan 11What We Learned About Bio-Gene Technology's (ASX:BGT) CEO CompensationRichard Jagger has been the CEO of Bio-Gene Technology Limited ( ASX:BGT ) since 2018, and this article will examine...
공시 • Dec 19Bio-Gene Technology Limited Appoints Peter Beetham as Non- Executive Director, Effective from 21 December 2020Bio-Gene Technology Limited announced the appointment of Dr. Peter Beetham as a Non- executive Director of the Company. Dr. Beetham is the co-founder and Chief Executive Officer of Cibus Global, LLC (Cibus). Dr. Beetham's appointment is effective from 21 December 2020. Dr. Beetham has over 30 years of experience in the bio-agriculture community, with a passion for moving technology to commercial application. He was employed by the Victorian Department of Agriculture and Rural Affairs (DARA) in Australia from 1985 to 1992, serving as a Scientific Officer based at the Plant Research Institute (PRI), working with research groups throughout Southeast Asia and the South Pacific.
공시 • Nov 26Bio-Gene Technology Limited Announces Changes of DirectorsBio-Gene Technology Limited announced in the Results of Meeting, Non-executive Chairman Don Brumley and Non-executive Director Kevin Rumble were not re-elected by shareholders at the 2020 Annual General Meeting (AGM) and have therefore retired as Directors of the Company effective at the close of the 2020 AGM. The Board is, and has been, on a path to make some changes that will result in the company benefitting from additional non-executive expertise. The Company is currently progressing discussions and the due diligence process with several potential candidates. Don, who led the Company to and through the IPO process and Kevin, whose passion as the founder of the Company has strongly supported the progress achieved to date. The remaining Directors have also resolved that Non-executive Director Robert Klupacs will act as the Company's Chairman in an interim capacity until the process of appointing new non-executive directors is concluded. The Company will make further announcements in that regard in due course.
공시 • Jun 19Bio-Gene Technology Limited has completed a Follow-on Equity Offering in the amount of AUD 0.427998 million.Bio-Gene Technology Limited has completed a Follow-on Equity Offering in the amount of AUD 0.427998 million. Security Name: Shares Security Type: Common Stock Securities Offered: 2,761,276 Price\Range: AUD 0.155